Shots: The P-III ATLANTIS study involves assessing Zepzelca (lurbinectedin, 2.0mg/m2) + doxorubicin vs topotecan/ CAV in 613 adult patients in a ratio (1:1) aged ≥18yrs. with SCLC whose disease progressed […]readmore
Tags : SCLC
Shots: The NDA submission is based on three clinical studies in which Trilaciclib was administered prior to chemotherapy treatment in patients with SCLC and has demonstrated robust myelopreservation benefits. The […]readmore
Shots: The approval is based on P-II assessing Zepzelca in 105 adults Ultragenyx with SCLC at 26 hospitals in the US and EU The study resulted in ORR was 35%, median […]readmore
Shots: Approval is based ongoing Ph 1/2 CheckMate-032, study is assessing 245 patients in two arms Opdivo vs platinum based therapy CheckMater-032 Results: ORR:12% (13/109); PR: 11% (12/109); CR: 0.9% […]readmore
Shots: Lurbinectedin (PM1183) a compound under clinical investigation an inhibitor of RNA polymerase II, essential for transcription process that is over-activated in tumors with transcription addiction The designation may provide […]readmore